Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis - PMLiVE The life-long condition affects approximately 1,900 people in Scotland

#hepatology #gastroenterology #Ipsen #Iqirvo #elafibranor #SMC #ScottishMedicinesConsortium #SMCapprovel #liverdisease #primarybiliarycholangitis #Scotland #NHSScotland #rarecholestaticliverdisease #NICE #NICErecommended #PBCpatients #ELATIVEtrial #cholestasis
pmlive.com/ipsens-iqirv...

SMC approves bimekizumab for hidradenitis suppurativa treatment - PharmaTimes The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have not

#dermatology #immunology #UCB #SMC #SMCapprovel #bimekizumab #hidradenitissuppurativa #HS #hidradenitissuppurativatreatment #ScottishMedicinesConsortium #NHSScotland #HSpatients #phase3clinicaltrial #BEHEARDI #BEHEARDII #clincialstudies #patientoutcomes
pharmatimes.com/news/smc-app...

Pfizer's Talzenna therapy accepted for use within NHS Scotland - PharmaTimes Scottish Medicines Consortium approves new option for mCRPC patients

#prostatecancer #Pfizer #Talzenna #talazoparib #Talzennatherapy #NHSScotland #ScottishMedicinesConsortium #SMCapprovel #mCRPCpatients #metastaticcastrationresistantprostatecancer #mCRPC #polyADPribosepolymeraseinhibitor #PARPinhibitor #metastaticprostatecancer
pharmatimes.com/news/pfizers...